<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032187</url>
  </required_header>
  <id_info>
    <org_study_id>LVTO-I</org_study_id>
    <nct_id>NCT01032187</nct_id>
  </id_info>
  <brief_title>Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children</brief_title>
  <acronym>LVTO</acronym>
  <official_title>Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Brasilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Brasilia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if amphotericin B is effective against visceral
      leishmaniasis in Brazilian children. Amphotericin B will be compared to meglumine antimoniate
      which is the current approved drug used for this disease in Brazil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite their high toxicity, antimonials and amphotericin B deoxycholate are commonly used
      for treating visceral leishmaniasis (VL). Few studies showing conflictive data about their
      efficacy and adverse events in pediatric population are available. This study aimed to
      evaluate efficacy and safety of amphotericin B deoxycholate vs. that of N-methylglucamine
      antimoniate in treating pediatric VL in Brazil. This was a randomized, open-label, 2-arm and
      controlled pilot clinical trial. Treatment naïve children and adolescents with VL without
      signs of severe illness were treated with N-methylglucamine antimoniate or amphotericin B
      deoxycholate. All patients were diagnosed with positive direct examination and/or positive
      PCR for Leishmania spp. performed in bone marrow samples. The primary efficacy end-point was
      VL cure determined after 180 days of completion of treatment. The analysis was performed
      using intention-to-treat (ITT) and per protocol (PP) analyses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Meglumine antimoniate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg/kg/day IV for 20 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anfo B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B-deoxycholate, 1mg/kg/day IV for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine antimoniate</intervention_name>
    <description>20mg/kg/day IV for 20 days</description>
    <arm_group_label>Meglumine antimoniate</arm_group_label>
    <other_name>Glucantime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B-deoxycholate</intervention_name>
    <description>Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days</description>
    <arm_group_label>Anfo B</arm_group_label>
    <other_name>Fungizone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical symptoms of visceral leishmaniasis: fever plus hepatomegaly or splenomegaly

          -  Diagnosis of visceral leishmaniasis confirmed through parasite visualization in bone
             marrow smears or positive serology (indirect immunofluorescent antibody test or rK39
             rapid test)or positive kDNA PCR test

        Exclusion Criteria:

          -  Any of the following laboratory findings

               -  Total serum bilirubin higher than 2,5 mg/dL

               -  Serum SGOT higher than 5 times the upper normal level

               -  Serum SGPT higher than 5 times the upper normal level

               -  Prothrombin time concentration lower than 70%

               -  Abnormal serum creatinine

          -  Any of the following signs or symptoms

               -  Generalized edema

               -  Severe malnutrition

               -  Systemic inflammatory response syndrome

          -  Any of the following conditions

               -  HIV infection/disease

               -  Diabetes

               -  Corticoid or immunosuppressive drugs use

               -  Symptomatic heart diseases

               -  Chronic hepatic or renal diseases

               -  Lupus erythematosus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myrlena RM Borges, MsC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Tocantins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo AS Romero, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Brasilia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Doenças Tropicais</name>
      <address>
        <city>Araguaína</city>
        <state>Tocantins</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dona Regina</name>
      <address>
        <city>Palmas</city>
        <state>Tocantins</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Borges MM, Pranchevicius MC, Noronha EF, Romero GA, Carranza-Tamayo CO. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil. Rev Soc Bras Med Trop. 2017 Jan-Feb;50(1):67-74. doi: 10.1590/0037-8682-0455-2016.</citation>
    <PMID>28327804</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Brasilia</investigator_affiliation>
    <investigator_full_name>Gustavo Adolfo Sierra Romero</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Visceral leishmaniasis</keyword>
  <keyword>Amphotericin B deoxycholate</keyword>
  <keyword>Meglumine antimoniate</keyword>
  <keyword>Children</keyword>
  <keyword>Brazil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Amphotericin B, deoxycholate drug combination</mesh_term>
    <mesh_term>Meglumine antimoniate</mesh_term>
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

